OS is a highly significant clinical endpoint—both from the patient’s and the clinician’s perspective—and is a widely accepted measure of benefit that can be easily and accurately assessed.
← all excerpts
Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab.
1
—
—